MET-097o

MET-097o is an oral, fully biased, ultra-long acting glucagon-like peptide 1 receptor agonist (GLP-1 RA) in development for the treatment of obesity and overweight. It is being developed by Metsera as part of a portfolio that includes both injectable and oral GLP-1 RAs. The drug is designed to provide potent weight loss effects with a long half-life, supporting less frequent dosing regimens compared to currently marketed peptide GLP-1 analogs. Preclinical studies indicate that MET-097o acts as a fully biased agonist at the glucagon-like peptide 1 receptor, activating cAMP signaling while minimizing ß-arrestin recruitment—a profile believed to enhance efficacy and tolerability. Clinical trials are ongoing to evaluate its safety and efficacy in individuals with obesity or overweight[5][6][7].